MARKET WIRE NEWS

Why The Pfizer-Trump Pharma Deal Is A Win For Branded Pharma, But Not For Consumers

Source: SeekingAlpha

2025-10-07 12:05:00 ET

By Diederik Stadig

What does the Pfizer-Trump deal cover?

The deal between the Trump Administration and Pfizer (PFE) provides clarity about the near-term future of the US patent-protected pharmaceutical sector after months of (tariff) uncertainty. If companies manufacture and invest in the US, they will be exempt from tariffs. This means that the margin risk from tariffs is largely muted, as branded pharma companies from the US, Europe, and Asia have already announced additional US investments in the next few years....

Read the full article on Seeking Alpha

For further details see:

Why The Pfizer-Trump Pharma Deal Is A Win For Branded Pharma, But Not For Consumers
ARK Genomic Revolution ETF

NASDAQ: ARKG

ARKG Trading

1.20% G/L:

$ Last:

223,320 Volume:

$36.28 Open:

mwn-link-x Ad 300

ARKG Latest News

November 28, 2025 03:18:58 pm
Why Tempus AI Stock Soared This Week
August 28, 2025 04:15:00 pm
How to Invest in Gene Stocks and ETFs
June 18, 2025 04:40:00 am
(ARKG) Technical Data

ARKG Stock Data

$1,108,567,347
37,932,159
N/A
N/A
US

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App